Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3JCVS)

• Drug Name: Terazosin Drug Info
• Synonyms: Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5401
  ChEBI ID: CHEMBL611
  CAS Number: CAS 63590-64-7
  TTD Drug ID: D0P9RF
  VARIDT Drug ID: DR00869
  ACDINA Drug ID: D00662

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
NOD-like receptor signaling pathway	-1.68	4.83e-2	145/181 (80.11%)	NFKBIA;NFKB1;PLCB4;...
Hematopoietic cell lineage	-1.69	4.87e-2	90/99 (90.91%)	CSF2;CD2;ITGAM;...
Chagas disease	-1.70	4.24e-2	93/102 (91.18%)	ADCY1;IRAK1;CALR;...
Pertussis	-1.70	4.42e-2	64/76 (84.21%)	IL1B;CXCL8;IRF3;...
Galactose metabolism	-1.71	4.62e-2	26/31 (83.87%)	PGM1;HKDC1;GLB1;...
IL-17 signaling pathway	-1.73	4.00e-2	84/94 (89.36%)	FOSB;TRAF5;TAB2;...
TNF signaling pathway	-1.75	3.97e-2	103/112 (91.96%)	TRAF5;TAB2;MMP9;...
Inflammatory bowel disease	-1.80	2.03e-2	58/65 (89.23%)	HLA-DOA;MAF;IL22;...
Staphylococcus aureus infection	-1.81	2.32e-2	72/95 (75.79%)	CFB;FPR2;C5AR1;...
NF-kappa B signaling pathway	-1.81	2.34e-2	90/104 (86.54%)	PLCG2;GADD45B;BCL2;...
Th1 and Th2 cell differentiation	-1.84	1.73e-2	80/92 (86.96%)	HLA-DRB1;JAG1;NFKBIA;...
Osteoclast differentiation	-1.86	1.62e-2	117/127 (92.13%)	FOSB;SPI1;TAB2;...
T cell receptor signaling pathway	-1.88	2.16e-2	93/104 (89.42%)	NFKBIA;NFKB1;PIK3CA;...
Viral protein interaction with cytokine and cytokine re...	-1.99	1.08e-2	84/100 (84%)	IL18;IL10RA;CCL13;...
Leishmaniasis	-2.01	2.16e-2	67/77 (87.01%)	IRAK1;TAB2;PRKCB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼